Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: A report from the CHART-2 Study

European Journal of Heart Failure

Volumn 16, Issue 3, 2014, Pages 309-316

  Takada, Tsuyoshi ^a   Sakata, Yasuhiko ^a   Miyata, Satoshi ^a   Takahashi, Jun ^a   Nochioka, Kotaro ^a   Miura, Masanobu ^a   Tadaki, Soichiro ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Heart failure; Heart rate; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SINUS RHYTHM; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

HEART FAILURE; HEART RATE; PROGNOSIS;

ADRENERGIC BETA-ANTAGONISTS; AGED; FEMALE; HEART FAILURE; HEART RATE; HUMANS; JAPAN; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME;

EID: 84896958092     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.22     Document Type: Article

References (30)

1. Wallhaus TR, Taylor M, De Grado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001;103:2441-2446.
2. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation 1992;85:1743-1750.
3. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008;117:2377-2387.
4. Nanchen D, Stott DJ, Gussekloo J, Mooijaart SP, Westendorp RG, Jukema JW, Macfarlane PW, Cornuz J, Rodondi N, Buckley BM, Ford I, Sattar N, De Craen AJ, PROSPER Group. Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. Eur J Heart Fail 2013;15:581-588.
5. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-894.
6. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators, on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
7. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001;103:1428-1433.
8. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
9. Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JG, Cohen-Solal A, Gheorghiade M, Gueyffier F, O'Connor CM, Fiuzat M, Patak A, Piña IL, Rosano G, Sabbah HN, Tavazzi L, Zannad F. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail 2014;16:76-85.
10. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
11. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray JJ, Solomon SD, CHARM Investigators. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012;59:1785-1795.
12. Kapoor JR, Heidenrech PA. Heart rate predicts mortality in patients with heart failure and preserved systolic function. J Card Fail 2010;16:806-811.
13. Maeder MT, Kaye DM. Different impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. Int J Cardiol 2012;155:249-256.
14. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H, CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan. First report from the CHART-2 study. Circ J 2011;75:823-833.
15. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, Shimokawa H, CHART-2 Investigators. Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study. Eur J Heart Fail 2012;14:367-376.
16. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, Fukumoto Y, Shiba N, Shimokawa H, CHART-2 Investigators. Prognostic impact of nutritional status in asymptomatic patients with cardiac diseases. Circ J 2013;77:2318-2326.
17. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
18. Lewis RJ. An introduction to classification and regression tree (CART) analysis. Presented at the 2000 Annual Meeting of the Society for Academic Emergency Medicine in San Francisco, California. http://citeseerx.ist.psu.edu/ viewdoc/download (11 september 2012).
19. Yohannes Y, Hoddinott J. Classification and regression trees: an introduction. 1999. http://www.ifpri.org/sites/default/files/pubs/themes/mp18/ techguid/tg03.pdf (11 september 2012).
20. Bui AL, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Yancy CW, Bhatt DL, Fonarow GC. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J 2013;165:567-574.e6.
21. Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, Ostergren J, McKelvie RS, Investigators of the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007;49:687-694.
22. Wannamethee G, Shaper AG, Macfarlane PW. Heart rate, physical activity, and mortality from cancer and other noncardiovascular diseases. Am J Epidemiol 1993;137:735-748.
23. Seccareccia F, Pannozzo F, Dima F, Minoprio A, Menditto A, Lo Noce C, Giampaoli S, Malattie Cardiovascolari Aterosclerotiche Istituto Superiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001;91:1258-1263.
24. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-1494.
25. f-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 2013;34:2839-2849.
26. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, Swedberg K, Tavazzi L. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013;102:11-22.
27. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-1263.
28. Beanlands RS, Nahmias C, Gordon E, Coates G, De Kemp R, Firnau G, Fallen E. The effects of β1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a doubleblind, placebo-controlled, positron-emission tomography study. Circulation 2000;102:2070-2075.
29. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009;53:184-192.
30. Yamamoto K, Origasa H, Hori M, J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013;15:110-118.